Core Insights - LifeMD reported Q2 2025 financial results with revenue of $62.2 million, a 23% increase year-over-year, but $4.1 million below consensus estimates [1][5] - The company experienced a GAAP EPS loss of $0.06, which was also below analyst expectations by $0.0517 [1][5] - Despite strong telehealth growth and improved operational profitability, the company reduced its full-year guidance due to segment-specific pressures, particularly in men's health [1][15] Financial Performance - Revenue (GAAP) for Q2 2025 was $62.2 million, up from $50.7 million in Q2 2024, reflecting a 22.8% year-over-year increase [2] - Adjusted EBITDA rose to $7.1 million from $2.2 million in Q2 2024, marking a 223% increase [2] - Telehealth revenue reached $48.6 million, a 30% increase from $37.4 million in Q2 2024 [2] - Active telehealth subscribers grew to nearly 297,000, up 16% year-over-year [5] Business Model and Growth Factors - LifeMD focuses on subscription-based telehealth services for chronic condition management, primary care, and specialty health [3] - The company emphasizes recurring telehealth subscriptions and expansion into new clinical verticals such as behavioral and women's health [4] - Key growth drivers include regulatory compliance, patient retention, and strategic partnerships with healthcare brands [4] Segment Performance - The telehealth segment is the main growth engine, with Telehealth Adjusted EBITDA increasing 560% to $3.4 million [6] - WorkSimpli revenue edged up 3% year-over-year, but active subscribers fell 6% as the company shifted focus to higher-value clients [7] - Gross margin decreased to 88% from 90% in the previous year, attributed to changes in revenue mix [8] Strategic Initiatives - LifeMD launched a national behavioral health service and is rolling out subscription-based virtual women's health programs [11] - The company enhanced its LifeMD+ membership program to aggregate various health services for better patient retention [11] - Strategic partnerships with weight management drug providers aim to improve patient access to therapies [13] Guidance and Outlook - For Q3 2025, total revenue is projected between $61 million and $63 million, with telehealth revenue expected to be $48 million to $50 million [16] - Full-year guidance was lowered to $250–$255 million in total revenue and $27–$29 million in Adjusted EBITDA due to ongoing challenges [15][17] - The company's near-term performance will depend on stabilizing subscriber growth and successfully integrating new verticals [17]